Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354701 · ClinicalTrials.gov registry record
COVID-19 and Cancer Consortium Registry
A clinical trial of COVID-19 and Invasive Malignancy (Any Type), sponsored by Vanderbilt-Ingram Cancer Center.
- Active
- Registry status
- 19,275
- Enrollment target
- 1
- Study location
NCT04354701: Active study of COVID-19 and Invasive Malignancy (Any Type), sponsored by Vanderbilt-Ingram Cancer Center.
NCT04354701 is a study of COVID-19 and Invasive Malignancy (Any Type) that is active but no longer recruiting, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 19,275 participants, below the 38,400-participant average among 298 other COVID-19 trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04354701, a study of COVID-19 and Invasive Malignancy (Any Type), is active but no longer recruiting, sponsored by Vanderbilt-Ingram Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 19,275 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt University Medical Center, with data donations from internal and external health care professionals.
Primary Outcome
The survey includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
Conditions Studied
Interventions
- OTHER Web-based REDCap survey
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19,275 participants |
| Start Date | 2020-03-17 |
| Est. Completion | 2029-12 |
What the registry record for NCT04354701 still lists
NCT04354701 is an observational study that tracks outcomes without assigning an intervention. Its 19,275 participants enrollment target places it among the larger protocols in the corpus, below the 38,400-participant average among 298 other COVID-19 trials with a reported enrollment target (50% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Web-based REDCap survey is the first listed.
NCT04354701 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT04354701 about?
NCT04354701 is a clinical study titled "COVID-19 and Cancer Consortium Registry". In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt University Medical Center, with data donations from internal and externa...
What is the current status of trial NCT04354701?
This trial is currently active not recruiting. The enrollment target is 19,275 participants. The study started on 2020-03-17. Estimated completion is 2029-12.
What conditions does trial NCT04354701 study?
This clinical trial studies the following conditions: COVID-19, Invasive Malignancy (Any Type).
What interventions are being tested in trial NCT04354701?
The interventions under investigation include: Web-based REDCap survey (OTHER).
Who is sponsoring clinical trial NCT04354701?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04354701 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04354701's enrollment target sits among peer trials
19,275 18th of 298 higher than 281 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05555095 · 19,331 participants
Examining Digital Health Care Delivery Models Through Medicaid Collaborative
- NCT07152249 · 19,480 participants · NA
Advancing Strategies to Optimize the PerIopeRativE Management of PostOperative Nausea and Vomiting (ASPIRE-PONV) Trial
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI